AstraZeneca is enjoying barnstorming growth in 2024 but is juggling big questions about its operations in China and ambitious plans to nearly double sales growth by 2030.
AstraZeneca Juggles Questions About China Scrutiny And US Growth Strategy
The UK-based major is set for near double-digit growth in 2024 but has become mired in concerns over a fraud probe in China on its third quarter call.
More from Earnings
More from Scrip
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.